Bajaj Healthcare profit and loss

Latest FY26

Revenue: ₹611cr+12.6% on FY25
EBITDA: ₹105cr+27.2% on FY25
Net profit: ₹15.8cr−60.1% on FY25
EPS: ₹4.98−62.5% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	656	611	543	473	673	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	6.3	7.1	19.4	8.7	1.6
	662	618	562	482	675
	352	306	307	264	520
	−11.8	10.2	−20.7	−9.7	−29.8
	68.5	62.8	57.1	43.8	47.8
	23.5	22.2	27.9	29.7	22.9
	29.5	27.5	27.9	27.6	27.4
	134	127	117	98.5	28.0
	596	556	516	454	617
	113	105	82.4	76.3	107
	83.8	77.3	54.5	48.6	79.5
Profit
	66.6	62.2	46.0	27.7	58.2
	−33.2	−33.2	0.0	−44.3	0.0
	33.4	28.9	46.0	−16.7	58.2
	0.0	0.0	0.0	0.0	15.7
	8.4	7.6	3.1	−2.3	−0.5
	8.4	7.6	3.1	−2.3	15.2
	20.6	15.8	39.5	−83.8	43.0
	25.0	21.3	42.9	−14.3	43.0
	−4.3	−5.5	−3.4	−69.5	0.0
	0.7	0.6	1.4	−2.8	0.3
	21.3	16.4	40.9	−86.6	43.3
Per share
	₹6.06	₹4.98	₹13.29	−₹30.36	₹15.59
	₹5.96	₹4.97	₹13.12	−₹30.36	₹15.59
Continuing & discontinued operations
	−3.5	−5.1	−4.0	−87.2	0.0
	0.8	0.4	−0.6	−17.7	0.0
Other comprehensive income — detail
	0.7	0.6	1.4	—	—
	0.9	0.8	1.8	−3.7	—
	0.2	0.2	0.5	—	—
	—	—	—	−0.9	−0.4
	—	—	—	0.0	0.1
Per share — as-filed variants
	₹7.42	₹6.73	₹14.45	−₹5.19	₹15.59
	₹7.32	₹6.72	₹14.26	−₹5.19	₹15.59
	−₹1.36	−₹1.75	−₹1.16	−₹25.17	₹0.00
	−₹1.36	−₹1.75	−₹1.14	−₹25.17	₹0.00
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	316	295	256	219	183
	48.2%	48.2%	47.2%	46.2%	27.1%
Adjusted (ex-exceptional items) — derived
	66.6	62.2	46.0	27.7	58.2
	−33.2	−33.2	0.0	−44.3	0.0
	45.5	40.3	39.5	−45.7	43.0
	₹13.37	₹12.72	₹13.29	−₹16.56	₹15.59

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

BAJAJHCARE₹314.45

Bajaj Healthcare Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersTHEMISMED LINCOLN WANBURY SIGACHI AHCL ANUHPHR AMRUTANJANMcap ₹1,059 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Revenue from Operations	673.3	473.4	542.6	611.0	655.8
Other Income	1.6	8.7	19.4	7.1	6.3
Total Income	674.9	482.1	562.0	618.2	662.1
Expenses
+ Cost of Materials Consumed	520.5	264.4	307.1	306.2	351.5
+ Changes in Inventories	-29.8	-9.7	-20.7	10.2	-11.8
+ Employee Benefit Expense	47.8	43.8	57.1	62.8	68.5
+ Finance Costs	22.9	29.7	27.9	22.2	23.5
+ Depreciation & Amortisation	27.4	27.6	27.9	27.5	29.5
+ Other Expenses	28.0	98.5	116.7	127.1	134.3
Total Expenses	616.7	454.5	516.0	556.0	595.5
EBITDA	106.8	76.3	82.4	104.8	113.3
EBIT	79.5	48.6	54.5	77.3	83.8
Profit
PBT before Exceptional Items	58.2	27.7	46.0	62.2	66.6
+ Exceptional Items	0.0	-44.3	0.0	-33.2	-33.2
Pretax Income	58.2	-16.7	46.0	28.9	33.4
+ Current Tax	15.7	0.0	0.0	0.0	0.0
+ Deferred Tax	-0.5	-2.3	3.1	7.6	8.4
Tax Expense	15.2	-2.3	3.1	7.6	8.4
Net Income	43.0	-83.8	39.5	15.8	20.6
+ Net Income — Continuing Ops	43.0	-14.3	42.9	21.3	25.0
+ Net Income — Discontinued Ops	0.0	-69.5	-3.4	-5.5	-4.3
+ Other Comprehensive Income	0.3	-2.8	1.4	0.6	0.7
Total Comprehensive Income	43.3	-86.6	40.9	16.4	21.3
Per Share
Basic EPS	15.59	-30.36	13.29	4.98	6.06
Diluted EPS	15.59	-30.36	13.12	4.97	5.96
Continuing & Discontinued Operations
+ Discontinued Operations — before Tax	0.0	-87.2	-4.0	-5.1	-3.5
+ Tax — Discontinued Operations	0.0	-17.7	-0.6	0.4	0.8
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	1.4	0.6	0.7
+ Items NOT to be Reclassified to P&L	—	-3.7	1.8	0.8	0.9
+ Tax on Items NOT to be Reclassified	—	—	0.5	0.2	0.2
+ Tax on Items NOT to be Reclassified — alt tag	-0.4	-0.9	—	—	—
+ Tax on Items to be Reclassified — alt tag	0.1	0.0	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	15.59	-5.19	14.45	6.73	7.42
Diluted EPS — Continuing Operations	15.59	-5.19	14.26	6.72	7.32
Basic EPS — Discontinued Operations	0.00	-25.17	-1.16	-1.75	-1.36
Diluted EPS — Discontinued Operations	0.00	-25.17	-1.14	-1.75	-1.36
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	182.6	218.6	256.2	294.6	316.1
Gross Margin %	27.13	46.18	47.21	48.22	48.21
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	58.2	27.7	46.0	62.2	66.6
− Exceptional Items (reconciliation)	0.0	-44.3	0.0	-33.2	-33.2
Net Income Adj (tax-effected)	43.0	-45.7	39.5	40.3	45.5
EPS Adj	15.59	-16.56	13.29	12.72	13.37
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	5.00	5.00	5.00	5.00	5.00
Filed Debt Equity	0.00	—	0.48	44.00	48.00
Filed Dscr	0.00	—	0.44	215.00	226.00
Filed Iscr	0.00	—	3.65	380.00	409.00
Paid Up Equity Capital	13.8	13.8	15.8	16.8	16.8

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.